alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsComparison of Separation Shock for Explosive and Nonexplosive Release Actuators on a Small Spacecraft PanelFunctional shock, safety, overall system costs, and emergence of new technologies, have raised concerns regarding continued use of pyrotechnics on spacecraft. NASA Headquarters-Office of Chief Engineer requested Langley Research Center (LaRC) study pyrotechnic alternatives using non-explosive actuators (NEA's), and LARC participated with Lockheed Martin Missile and Space Co. (LMMSC)-Sunnyvale, CA in objectively evaluating applicability of some NEA mechanisms to reduce small spacecraft and booster separation event shock. Comparative tests were conducted on a structural simulator using five different separation nut mechanisms, consisting of three pyrotechnics from OEA-Aerospace and Hi-Shear Technology and two NEA's from G&H Technology and Lockheed Martin Astronautics (LMA)-Denver, CO. Multiple actuations were performed with preloads up to 7000 pounds, 7000 being the comparison standard. All devices except LMA's NEA rotary flywheel-nut concept were available units with no added provisions to attenuate shock. Accelerometer measurements were recorded, reviewed, processed into Shock Response Spectra (SRS), and comparisons performed. For the standard preload, pyrotechnics produced the most severe and the G&H NEA the least severe functional shock levels. Comparing all results, the LMA concept produced the lowest levels, with preload limited to approximately 4200 pounds. Testing this concept over a range of 3000 to 4200 pounds indicated no effect of preload on shock response levels. This report presents data from these tests and the comparative results.Document ID19970010358Acquisition SourceLangley Research CenterDocument TypeTechnical Memorandum (TM)AuthorsLucy, M. H.*(NASA Langley Research Center Hampton, VA United States)*Buehrle, R. D.*(NASA Langley Research Center Hampton, VA United States)*Woolley, J. P.*(Lockheed Martin Missile and Space Sunnyvale, CA United States)*Date AcquiredSeptember 6, 2013Publication DateDecember 1, 1996Subject CategorySpacecraft Design, Testing And PerformanceReport/Patent NumberNAS 1.15:110257NASA-TM-110257Accession Number97N15548Funding Number(s)PROJECT: RTOP 233-10-14-04Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Available DownloadsNameType19970010358.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
TheHonorable Mary Ann L. Medler, United States Magistrate Judge for th e 1 Eastern Dis trict of Missouri, to whom the case was referred for final disposition b y consent of the parties pursuant to 28 U.S.C. § 636(c).



## United States Court of Appeals FOR THE EIGHTH CIRCUIT

___________ No. 98-2081

___________ Monty Ross, * * Appellant, * * Appeal from the United States v. * District Court for the * Eastern District of Missouri. Joel Bautista, M.D.; Correctional * Medical Services, * [UNPUBLISHED] * Appellees. *

___________ Submitted: August 31, 1998 Filed: September 4, 1998

___________ Before FAGG, BEAM, and LOKEN, Circuit Judges.

___________ PER CURIAM. Monty Ross, a Missouri prisoner, appeals from the district c ourt & s adverse grant 1 of summary judgment in this 42 U.S.C. § 1983 action. We h ave carefully reviewed the reco rdand the parties & briefs, and affirm the judgment of the district court for th e reasons set forth in its memorandum. See 8th Cir. R. 47B.-2-

A true copy. Attest: CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
Case No. 10,183a.

#### NEW ORLEANS, M. & C. R. CO. v. NEW ORLEANS.

[See 14 Fed. 373.]
Footnote addressing possiblie use of monitoring alone

Lydia Wegman 

to: 

james_a._laity, dmancini 

06/01/2010 08:00 PM 

Cc: 

Richard Wayland, Scott Mathias, Sara Schneeberg, Kevin McLean, James Hemby, Larry Wallace, 

Tricia Crabtree 

Show Details 

Jim and Dom, 

 

Please find attached a footnote we would add to Section III that addresses the 

possibility that in some areas we could rely on monitoring alone, rather than 

monitoring and modeling, to determine attainment. This addresses the issue we 

discussed this morning. The attached language would go on page 7 of section III, 

in the first full paragraph that includes footnote 2. In the complete FRM from May 

4, it would go at the top of page 115. We hope this addresses your concern. 

 

Lydia 

Page 1 of 1

file://C:\Documents and Settings\tcrabtre\Local Settings\Temp\notesFCBCEE\~web0279.htm 6/2/2010
From: jsisk0157@charter.net

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 3:15:44 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients. If you do not reverse course I ask you to expand conscience protections for

any organizations that provide individual and group insurance and have moral or religious objections. I

strongly oppose the government forcing free insurance coverage on Americans especially for drugs and

devices that I oppose because some of these can cause an abortion (such as ella and Plan B).

I also ask you to reconsider your definition of religious employer and offer an authentic conscience

protection for any organization and business that has moral or religious objection to providing such

insurance to their employees. This legal mandate clearly violates the spirit of conscience laws which

prohibit government discrimination against those who object to various health services on moral or

religious grounds. The definition of "religious employer" in the regulation is so narrow as to only include

churches, but will still mean that a host of businesses and organizations that have conscience objections

will be required to choose between either violating their conscience or not being able to offer employees

health insurance.

Please protect the conscience rights of insurers, providers and people like me who object to being

forced by the federal government to offer or subsidize contraceptives and sterilization services, especially

when some of these drugs can take the life of early unborn children. No Americans should be forced by

the federal government to essentially subsidize services they object to. I again urge you in the strongest

way possible to reverse course and remove contraceptives and sterilizations from the list of mandatory

preventive services.

Sincerely,

John Sisk

Spartanburg, SC 29301
Exhibit 32.2

CERTIFICATION PURSUANT TO

SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED
STATES CODE,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to
Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as Acting Chief Financial Officer and Principal Accounting Officer of GigOptix, Inc. (the
Company), does hereby certify that to the undersigneds knowledge:

1) the
Companys Form 10-K for the year ended December 31, 2010 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2) the information contained in the Companys Form 10-K for the year ended December 31, 2010 fairly
presents, in all material respects, the financial condition and results of operations of the Company.



|                                                                                       
|---------------------------------------------------------------------------------------
|                                                                                       
|/s/    Jeffrey Parsons                                                                 
|Jeffrey Parsons                                                                        
|Acting Chief Financial Officer and Principal Financial and Principal Accounting Officer

Dated: March 2, 2011
EXHIBIT 35.1
 VW Credit, Inc. Servicer Compliance Statement Under Section 3.9 of the Sale and Servicing Agreement and Item 1123 of Regulation AB
 
   1.
    
    A review of the activities of the Servicer during the period from January 1, 2010
through December 31, 2010, and of its performance under the Sale and Servicing Agreement
was conducted under my supervision.2.
    
    To the best of my knowledge, based on such review, the Servicer has, fulfilled all of
its obligations under the Sale and Servicing Agreement in all material respects throughout
such period, except that, with respect to the Applicable Servicing Criterion in Paragraph
(d)(2)(i) of Item 1122, on April 8, 2010 a systems reporting deficiency caused a batch of
payments to be transferred to the collection account on the third business day rather than
the two business days as required under the transaction agreements; however, there was no
adverse impact to the Noteholders. The above mentioned deficiency was identified during
the Companys daily reconciliation process; however, process verification delayed the
transfer.
  /s/ Andrew StuartAndrew StuartExecutive Vice President & CFO
Exhibit 32.1

      Certification of Chief Executive Officer and Chief Financial Officer
            Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

     I,  Klaus  Eckhof,  President  and  Chief  Executive Officer of Aurora Gold
     Corporation  (the  "Company"),  certify,  pursuant  to  Section  906 of the
     Sarbanes-Oxley  Act  of  2002,  that  to  my  knowledge:

1.   The  Quarterly  Report  on  Form 10-QSB of the Company for the period ended
     March 31, 2006 which this certification accompanies fully complies with the
     requirements  of  section  13(a) or 15(d) of the Securities Exchange Act of
     1934:  and

2.   The  information  contained  in the Report fairly presents, in all material
     respects, the financial condition and results of operations of the Company.


Date:     April19,  2006              BY:  /s/  Klaus  Eckhof
          --------------                   ------------------
                                           Klaus  Eckhof
                                           President and Chief Executive Officer


This  certification  accompanies  this  Report  pursuant  to  Section 906 of the
Sarbanes-Oxley  Act  of  2002  and  shall not be deemed filed by the Company for
purposes  of  Section  18  of the Securities Exchange Act of 1934, as amended. A
signed  original  of  this  written  statement required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears  in  typed  form within the electronic version of this written statement
required  by  Section 906, has been provided to the Company and will be retained
by  the  Company  and furnished to the Securities and Exchange Commission or its
staff  upon  request.
**EXHIBIT 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Peter S. Garcia, Chief Financial Officer of Marina Biotech, Inc. (“Marina Biotech”), certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, that the Annual Report of Marina Biotech on Form 10-K for the year ended December 31, 2010 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended,and that information contained in the Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of Marina Biotech. 

Date: March 23, 2011

A signed original of this written statement required by Section 906 has been provided to Marina Biotech and will beretained by Marina Biotech and furnished to the Securities and Exchange Commission or its staff upon request. 

Thiscertification accompanies each periodic report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by Marina Biotech for purposes ofSection 18 of the Securities Exchange Act of 1934, as amended.
Here's how you know
 **Official websites use .mil** .mil
 **Secure .mil websites use HTTPS** lock () https://


Skip to main content (Press Enter).
 Toggle navigation
            
            U.S. Central Command
                CENTCOM
        Search
                    Search CENTCOM:
                        Search
                Search CENTCOM:
                    Search
    Home

    ABOUT US
    
        COMMAND PRIORITIES

    LEADERSHIP

    COMPONENT COMMANDS

    HISTORY

    POSTURE STATEMENT

    CENTCOM AOR
    
        CENTCOM COALITION

    OPERATIONS AND EXERCISES
    
        USMTM

    CONTACT
    
        OPERATIONAL CONTRACT SUPPORT

    COMMUNITY RELATIONS

    THEATRE MEDICAL CLEARANCE

    INNOVATION VENDOR PORTAL

    MILITARY MEMBER INNOVATION PORTAL

    MEDIA
    
        SOCIAL MEDIA

    NEWS ARTICLES

    PRESS RELEASES

    STATEMENTS

    IMAGERY

    VIDEOS

    TRANSCRIPTS

    VISITORS AND PERSONNEL
    
        FAMILY CENTER

    FAMILY READINESS

    CENTCOM WEBMAIL

    SOCIAL MEDIA SECURITY

    ACCOUNTABILITY

    EMERGENCY PREPAREDNESS

    USCENTCOM UNCLASSIFIED REGULATIONS

    FOIA LIBRARY

    INNOVATION OASIS

    WELCOME GUIDE  Search
 Search
 All Images All ImagesCommunity RelationsOtherPreviousCommanders
 Upload Date Upload DatePhoto DateTitle
  Share
  
 Small () Medium () Full Size (1.37 MB)
 Photo Gallery
 About UsCommand PrioritiesLeadershipComponent
   CommandsHistoryPosture Statement
   Area of
   ResponsibilityCENTCOM Coalition
   Operations And
   ExercisesOperation Inherent
   ResolveResolute Support
   MediaSocial MediaNews ArticlesPress ReleasesVideo And Imagery
   Visitors And
   PersonnelFamily ReadinessCENTCOM WebmailSocial MediaSecurityAccountabilityEmergency
   Preparedness
   ContactCommunity Relations
                    Stay Connected
                
                Privacy & Security  Inspector General  FOIA  Privacy Act
            

Hosted by Defense Media Activity - WEB.mil
EX-10.4



 Exhibit 10.4 
 [Armstrong World Industries, Inc. Letterhead] 
 December 31, 2012 

Mr. Matthew Espe 
 Chief Executive
Officer & President 
 Armstrong World Industries, Inc. 
 2500 Columbia Avenue 
 Lancaster PA 17603 
 Re: Employment Agreement – Section 409A  
 Dear Matt: 

You and Armstrong World Industries, Inc. (the “Company”) are parties to an Employment Agreement dated as of June 24, 2010 (the
“Agreement”), which sets forth the terms of your employment with the Company. 
 In order to comply with section 409A of the Internal
Revenue Code, you and the Company agree that the Agreement is amended as follows: 
 Section 9 is amended by adding a sentence to the end
to read as follows: 
 Notwithstanding any provision of this Agreement to the contrary, (i) in no event may Executive,
directly or indirectly, designate the calendar year of a payment, and (ii) if and to the extent that payments under Section 8(d)(iii) or (v) are subject to Section 409A of the Code, such payments will be made or commence, as
applicable, on the sixtieth (60th) day following Executive’s date of termination of employment, subject to Executive executing and not revoking a release of claims as described above. 

In all respects not amended, the Agreement is ratified and confirmed. 
 Please confirm your agreement to this amendment by signing the enclosed copy of this letter and returning it to Thomas M. Kane, Sr. Vice President, Human Resources & Government Relations.

 Very truly yours, 
  

			
	 Armstrong World Industries, Inc.

		
	 By:
	 	 /s/ Mark A. Hershey


 As its Senior Vice President, General Counsel and Secretary 

 

	
	CONFIRMED AND AGREED
	as of the date first set forth above:
	
	 /s/ Matthew Espe

	Matthew Espe
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required).                    

*Date:*                         October 18, 2023.                    

*Time:*                         1:00 p.m. to 4:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F52, Rockville, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Lindsey M. Pujanandez, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities,  National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F52, Rockville, MD 20852, (240) 627-3206,                         *lindsey.pujanandez@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: September 14, 2023.

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory Committee Policy. 

[FR Doc. 2023-20320 Filed 9-19-23; 8:45 am]

BILLING CODE 4140-01-P
EXHIBIT 31
CERTIFICATION OF SENIOR OFFICER IN CHARGE OF THE SERVICING FUNCTION OF THE SERVICER PURSUANT TO
Rule 15d-14(d)
  1.
    
    I have reviewed this report on Form 10-K, and all reports on Form 10-D required to be
filed in respect of the period covered by this report on Form10-K of Volkswagen Auto Loan
Enhanced Trust 2008-1 (the Exchange Act periodic reports);2.
    
    Based on my knowledge, the Exchange Act periodic reports, taken as a whole, do not
contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were
made, not misleading with respect to the period covered by this report;3.
    
    Based on my knowledge, all of the distribution, servicing and other information
required to be provided under Form 10-D for the period covered by this report is included
in the Exchange Act periodic reports;4.
    
    I am responsible for reviewing the activities performed by the servicer and based on my
knowledge and the compliance review conducted in preparing the servicer compliance
statement required in this report under Item 1123 of Regulation AB, and except as disclosed
in the Exchange Act periodic reports, the servicer has fulfilled its obligations under the
servicing agreement in all material respects; and5.
    
    All of the reports on assessment of compliance with servicing criteria for asset-backed
securities and their related attestation reports on assessment of compliance with servicing
criteria for asset-backed securities required to be included in this report in accordance
with Item 1122 of Regulation AB and Exchange Act Rules 13a-18 and 15d-18 have been included
as an exhibit to this report, except as otherwise disclosed in this report. Any material
instances of noncompliance described in such reports have been disclosed in this report on
Form 10-K.
   /s/Andrew StuartAndrew StuartExecutive Vice President & CFO
(senior officer in charge of the servicing function)
From: emontfort@artselectric.com

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 1:11:15 PM

To Whom It May Concern:

I am writing today to ask in the strongest way possible that you rescind the unjust and coercive

mandate that all "contraceptives" and sterilization procedures be covered by private health insurance

with no co-pay to patients.

I, like millions of other Americans, do not want a penny of my money to be spent on paying for

abortions or anything that promotes abortions. My husband owns his own company that employes

approximately 160 people. We do not want to pay for abortions in the insurance policy we offer our

employees.

When will you accept the fact that the majority of Americans oppose abortion on demand. Stop trying

to force it down our throats or trick us into having to pay for it.

Sincerely,

Eunice Montfort

Frankfort, KY 40601